Market Intelligence, Clinical Progress, and High-Purity Reagents for ADCC-Enhanced Antibody and NK Cell Engager Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FCGR3A (CD16a) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (V158 High Affinity) | FCGR3A (CD16a) V158 ECD-Fc Fusion. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). Theoretical MW ~45-55 kDa. | View FCGR3A Products |
| Antigen (F158 Low Affinity) | FCGR3A (CD16a) F158 ECD-Fc Fusion. Low-affinity polymorph for population coverage assessment. Sequence Verified. | View FCGR3A Products |
| Gene Delivery | FCGR3A Promise-ORF / Lentivirus Premade Particles. Full-length ORF (V158 or F158) for stable effector cell line construction. | View FCGR3A Products |
| Benchmark Ab | Anti-FCGR3A (CD16a) Reference Antibody (including AFM13 analog sequences). Recombinant positive control for binding/blocking assays and receptor occupancy. Sequence Verified. | View FCGR3A Products |
| Validator | FCGR3A siRNA Set. For knockdown verification in NK cell or macrophage models to ensure target specificity. | View FCGR3A Products |
| Related Target: FCGR2A | FCGR2A (CD32a). Activating Fc receptor co-expressed on macrophages. Critical for selectivity profiling of Fc-engineered antibodies and ADCP mechanism deconvolution. | View FCGR2A Products |
| Related Target: FCGR3B | FCGR3B (CD16b). Neutrophil-specific GPI-anchored homolog (96% ECD homology). Essential for off-target binding discrimination to avoid sink effects. | View FCGR3B Products |
| Related Target: NKG2A | NKG2A (KLRC1). Key NK cell checkpoint; combination target for enhanced NK cell activation strategies. | View NKG2A Products |
| Related Target: HER2 | HER2 (ERBB2). Classic tumor antigen for ADCC reporter assay positive control and co-targeting validation. | View HER2 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| F158/V158 Polymorphism Affinity Variation (including rs10127939, rs443082) | Matched pair proteins (V158 High Affinity & F158 Low Affinity) with >95% purity, sequence-verified alleles for patient stratification modeling. Both Ig-like C2-type domains (UniProt P08637) are intact. |
| Fc Engineering Validation (Afucosylation, LALA, YTE) | HEK293-expressed native glycosylation patterns ensuring accurate SPR/BLI binding kinetics for Fc-modified antibodies. |
| Cross-Reactivity Counter-Screening (FcγR Family) | Homolog panel (FCGR1A/CD64, FCGR2A/CD32a, FCGR2B/CD32b, FCGR3B/CD16b) strictly verified by mass spec for selectivity assays. |
| Lack of Neutralizing/Blocking Controls | High-affinity Anti-FCGR3A reference antibody included for competitive binding/blocking and receptor occupancy studies. |
| Cell Surface Expression Validation | Validated siRNA sets for knockdown confirmation in primary NK cell or reporter cell assays. |
| Cross-species Preclinical Evaluation | Human, Cynomolgus, and Mouse ortholog proteins available; HEK293 expressed to preserve species-specific glycosylation patterns. |
| Receptor Occupancy & Ligand Competition | Benchmark antibodies and full-length lentivirus systems support RO assays and IgG-competition studies in NK reporter lines. |
Live FCGR3A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (FCGR3A/CD16a/ADCC)
- ➤ NK Cell Engager Clinical Trials (CD16/FCGR3A)
- ➤ Latest Resistance Research (V158F Pharmacogenomics)
- ➤ Latest NK Cell Engager Research
- ➤ Recent Patent Filings (Fc Engineering & Bispecifics)
- ➤ FCGR3A Patent Filings (General)
Global Clinical Landscape & Future Outlook
The therapeutic focus on FCGR3A (CD16a) has evolved from indirect ADCC enhancement via Fc engineering to direct engagement strategies. The race is dominated by Fc-engineering technologies (afucosylation, glycoengineering) and CD16a-engaging bispecifics (BiKEs, TriKEs, ICEs) designed to retarget NK cells against tumors. First-generation ADCC-enhanced antibodies (e.g., Obinutuzumab) have established clinical benchmarks, while next-generation molecules pursue precision Fc optimization—tailoring affinity to specific V158/F158 patient genotypes and minimizing off-target engagement with inhibitory receptors like FCGR2B. Emerging modalities include trispecific constructs co-engaging CD16a, IL-15, and tumor antigens (e.g., GT Biopharma's TriKE platform) to sustain NK cell proliferation and bypass T-cell exhaustion. Direct CD16a agonist antibodies (e.g., Innate Pharma) aim to activate NK cells independently of antibody-based tumor targeting. As clinical validation moves from hematologic malignancies into solid tumors, the demand for pharmacogenomics-ready reagents—including matched V158/F158 variant proteins and comprehensive FcγR family panels—continues to grow.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Afucosylated / ADCC-Enhanced mAbs | Roche/Genentech, Kyowa Kirin, Takeda, AstraZeneca, MacroGenics | B-cell Lymphomas, Autoimmune, Solid Tumors | Polymorphic Binding Assay (V158 & F158 proteins for affinity ranking); Cyno ortholog for toxicology bridging |
| CD16a-Engaging Bispecifics / Innate Cell Engager (ICE) | Affimed, Innate Pharma, Xencor | Hodgkin Lymphoma, Solid Tumors, Hematologic Malignancies | Selectivity Panel (FCGR2A/3B homologs to rule out off-target binding); High-purity CD16a ECD for SPR/BLI |
| TriKE (CD16×IL15×TAA) & Trispecifics | GT Biopharma, Academic Partners | AML, Solid Tumors | Binding Kinetics (high-purity ECD proteins); IL-15/CD16a functional assays |
| Fc-Engineered Variants (LALA, YTE, aglycosyl) | AstraZeneca, Xencor, MacroGenics | Immuno-oncology, Long-acting Biologics | HEK293-expressed CD16a for native glycan interaction studies; cross-species orthologs |
| CAR-NK & Cell Therapy | NKarta, Fate Therapeutics, Academic Partners | Refractory Leukemia, Hematologic Cancers | Stable Cell Line Construction (Lentivirus with V158/F158 ORFs); CD16a expression quantification |
| Direct Anti-CD16a Agonist Antibodies | Innate Pharma, Early Biotech | Oncology | Receptor Occupancy Assay; Non-ligand blocking epitope verification; Selectivity vs FCGR3B |